Nasdaq · CIK 0001766140
UNCY Unicycive Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing May 21, 2026.
Unicycive Therapeutics, Inc. (UNCY) has 11 SEC Form 4 filings on file from 7 insiders, the latest filed on May 21, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Unicycive Therapeutics, Inc., scored.
Transactions
Every row filed, 13 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | Shalabh K. Gupta CEO | AGrant or award Restricted Stock Unitsderivative | +762,200 | $0.00 | $0 | 762,200 | May 21, 2026 |
| May 14, 2026 | Pramod Gupta EVP, Pharmaceuticals and BD | AGrant or award Restricted Stock Unitderivative | +169,500 | $0.00 | $0 | 169,500 | May 20, 2026 |
| Aug 25, 2025 | Gaurav Aggarwal director | CConversion Common Stockindirect: By Vivo Opportunity Fund Holdings L.P. | +652,900 | - | - | 1,789,915 | Aug 26, 2025 |
| Aug 25, 2025 | Gaurav Aggarwal director | DDisposition to issuer Series A-2 Prime Preferred Stockderivativeindirect: By Vivo Opportunity Fund Holdings L.P. | -3,199 | $1,000.00 | $3.2M | 0 | Aug 26, 2025 |
| Jul 28, 2025 | Gaurav Aggarwal director | AGrant or award Stock Optionsderivative | +21,200 | $0.00 | $0 | 39,200 | Jul 30, 2025 |
| Jul 28, 2025 | Pramod Gupta EVP, Pharmaceuticals and BD | AGrant or award Stock Optionsderivative | +90,000 | $0.00 | $0 | 301,986 | Jul 30, 2025 |
| Jul 28, 2025 | Shalabh K. Gupta CEO | AGrant or award Stock Optionsderivative | +325,000 | $0.00 | $0 | 968,951 | Jul 30, 2025 |
| Jul 28, 2025 | Douglas Jermasek EVP of Corporate Strategy | AGrant or award Stock Optionsderivative | +10,000 | $0.00 | $0 | 215,500 | Jul 30, 2025 |
| Jul 28, 2025 | Sara Kenkare-Mitra director | AGrant or award Stock Optionsderivative | +21,200 | $0.00 | $0 | 39,200 | Jul 30, 2025 |
| Jul 28, 2025 | Sandeep Laumas director | AGrant or award Stock Optionsderivative | +21,200 | $0.00 | $0 | 41,286 | Jul 30, 2025 |
| Jul 28, 2025 | John Townsend Chief Financial Officer | AGrant or award Stock Optionsderivative | +10,000 | $0.00 | $0 | 101,557 | Jul 30, 2025 |
| Feb 18, 2025 | Gaurav Aggarwal director | CConversion Common Stockindirect: By Vivo Opportunity Fund Holdings L.P. | +1,400,000 | - | - | 11,370,152 | Feb 19, 2025 |
| Feb 18, 2025 | Gaurav Aggarwal director | DDisposition to issuer Series A-2 Prime Preferred Stockderivativeindirect: By Vivo Opportunity Fund Holdings L.P. | -686 | $1,000.00 | $686k | 3,119 | Feb 19, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Gaurav Aggarwaldirector
- Pramod GuptaEVP, Pharmaceuticals and BD
- Shalabh K. GuptaCEO
- Douglas JermasekEVP of Corporate Strategy
- Sara Kenkare-Mitrapresident, officer, director
- Sandeep Laumascfo, officer, director
- John TownsendChief Financial Officer
Questions about UNCY
Answered from the filings on this page, as of the latest one.
Are insiders buying UNCY?
No. In the last 90 days no insider at Unicycive Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade UNCY on the open market?
No open-market trade has been scored at Unicycive Therapeutics, Inc.. The latest Form 4 on file was filed on May 21, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Unicycive Therapeutics, Inc.?
7 people have filed a Form 4 at Unicycive Therapeutics, Inc., among them Gaurav Aggarwal (director), Pramod Gupta (EVP, Pharmaceuticals and BD), Shalabh K. Gupta (CEO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.